Through our research efforts we have evaluated over 100+ compounds for their serotonin receptor binding profiles via 5-HTome, the majority of which can be categorized in two broad drug development programs: 1) 5-HT2A agonist program with low 5-HT2B liability, and 2) 5-HT2C selective program with low 5-HT2A and 5-HT2B liability.
5-HT2A receptor agonist exhibiting multi-receptor selectivity
- Inactive at 5-HT2B receptor
- Non-hallucinogenic
- Therapeutic indications: treatment-resistant depression (TRD); PTSD
Selective 5-HT2C receptor agonist
- Low Activity/Inactivity at 5HT1A, 5-HT2A and 5-HT2B receptors
- Non-hallucinogenic
- Therapeutic indications: schizophrenia; Alzheimer’s-induced psychosis; eating disorders
